SCHEMBL1829577

SCHEMBL1829577

C1CCCC2(CC1)CCCNC2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
CYP3A4 P08684 6/20 0.40
CYP2D6 P10635 5/20 0.40
CYP1A2 P05177 4/20 0.40
USP2 O75604 3/20 0.40
HSD17B10 Q99714 3/20 0.39
TSHR P16473 2/20 0.39
CYP2C9 P11712 1/20 0.37
MAPK1 P28482 2/20 0.36
HPGD P15428 2/20 0.36
TP53 P04637 1/20 0.36
CYP2C19 P33261 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CHEK1 O14757 1/20 0.36
AURKA O14965 1/20 0.36
RPS6KA5 O75582 1/20 0.36
CHEK2 O96017 1/20 0.36
ABL1 P00519 1/20 0.36
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1793681 1.00 ALDH1A1 (0.40) ALDH1A1CYP3A4CYP2D6CYP1A2USP2
SCHEMBL1793924 0.97 CYP2D6 (0.41) ALDH1A1CYP3A4CYP2D6CYP1A2USP2
SCHEMBL11013028 0.94 ALDH1A1 (0.44) ALDH1A1CYP3A4CYP2D6CYP1A2USP2
SCHEMBL17609103 0.94 ALDH1A1 (0.44) ALDH1A1CYP3A4CYP2D6CYP1A2USP2
SCHEMBL7774907 0.94 ALDH1A1 (0.44) ALDH1A1CYP3A4CYP2D6CYP1A2USP2
SCHEMBL16878563 0.92 ALDH1A1 (0.42) ALDH1A1CYP3A4CYP2D6CYP1A2USP2
SCHEMBL17797726 0.92 ALDH1A1 (0.42) ALDH1A1CYP3A4CYP2D6CYP1A2USP2
SCHEMBL16878393 0.92 ALDH1A1 (0.42) ALDH1A1CYP3A4CYP2D6CYP1A2USP2
SCHEMBL1796659 0.91
SCHEMBL16878332 0.91 ALDH1A1 (0.39) ALDH1A1CYP3A4CYP2D6CYP1A2USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022200523-A9 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2023-02-16 WO disclosed
US-20190263804-A1 AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2019-08-29 US disclosed
US-10202387-B2 Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors JANSSEN PHARMACEUTICA NV (BE) 2019-02-12 US disclosed
US-20180057496-A1 HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS JANSSEN-CILAG (FR) 2018-03-01 US disclosed
US-20110230419-A1 IAP BINDING COMPOUNDS NUEVOLUTION A/S (DK) 2011-09-22 US disclosed
EP-2318363-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS Nuevolution A/S (DK) 2011-05-11 EP disclosed
WO-2009152824-A1 HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS NUEVOLUTION A/S (DK) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190263804-A1 AZABENZIMIDAZOLE DERIVATIVES AS PI3K BETA INHIBITORS PIK3CD, PIK3CB, PIK3CA ALDH1A1 1422/4885CYP3A4 344/4885CYP2D6 1100/4885
US-10202387-B2 Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors PIK3CB, PIK3CD, PIK3CA ALDH1A1 1880/4885CYP3A4 375/4885CYP2D6 741/4885
US-20110230419-A1 IAP BINDING COMPOUNDS BIRC5, BIRC7, BIRC3 ALDH1A1 2947/4885CYP3A4 3839/4885CYP2D6 3267/4885
US-20180057496-A1 HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS PIK3CB, PIK3CD, PIK3CA ALDH1A1 1880/4885CYP3A4 375/4885CYP2D6 741/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.